Table 2.
Men at Risk for a Repeated Prostate Cancer Biopsy
| Variable | Reference scenario (standard of care) | New scenario (epigenetic assay) |
|---|---|---|
| Men at risk of repeated biopsy, N | 2101 | 2101 |
| Men referred for repeated biopsy or methylation test, % | 43 | 43 |
| Number of men referred for repeat biopsy or methylation test, N | 903 | 903 |
| Number of men with ASAP, % | 3 | 3 |
| Cases with sufficient tissue for methylation test, % | N/A | 99.9% |
| Risk stratification based on methylation markers | ||
| Evaluable cases, N | N/A | 875 |
| Cases with positive methylation markers, N | N/A | 365 |
| Cases with negative methylation markers, N | N/A | 510 |
| Total men referred for repeated biopsy, N | 903 | 365 |
ASAP indicates atypical small acinar proliferation; N/A, not applicable.